首页 | 本学科首页   官方微博 | 高级检索  
检索        

微RNA-374b与前列腺癌恶性程度及生化复发的分析
引用本文:陈彦飞,陈雁如,吴永定,杨盛帮,莫汝均,凌晓辉,江福能,钟惟德.微RNA-374b与前列腺癌恶性程度及生化复发的分析[J].中华生物医学工程杂志,2014(5):347-350.
作者姓名:陈彦飞  陈雁如  吴永定  杨盛帮  莫汝均  凌晓辉  江福能  钟惟德
作者单位:广州医科大学附属广州市第一人民医院泌尿外科广东省临床分子医学及分子诊断重点实验室,510180
基金项目:国家自然科学基金(30872960、81200550);广东省科技计划项目(20128031800008);广东省泌尿外科重点实验室项目(2010A060801016);广州市卫生局重点项目(201102A212015)
摘    要:目的检测前列腺癌组织及良性前列腺组织中微RNA-374b表达,探讨其与前列腺癌恶性程度及生化复发的关系。方法收集广州医科大学附属广州市第一人民医院、中山大学附属第二医院、广州市红十字会医院2000年至2010年泌尿外科103例前列腺癌手术后的样本和25例前列腺增生手术获取的前列腺良性组织样本。采用原位杂交技术检测微RNA.374b在前列腺癌组织及良性前列腺组织中表达,并对微RNA.374b表达与前列腺癌患者年龄、术前PSA、临床分期、病理分期、Gleason评分、是否生化复发、是否转移及是否死亡的关系进行统计分析。根据微RNA.374b的相对表达量,以中位数(M=4.50)将其分为低表达组及高表达组,运用Kaplan.meier方法及Log.rank检验进行总体生存率和无生化复发生存率分析。结果微RNA.374b在前列腺癌的表达低于良性组织(3.97±1.17比4.70±0.71,P〈0.05)。微RNA.374b的表达量同Gleason评分、病理分期、转移、是否生存及生化复发有关(均P〈0.05),同年龄、PSA水平及临床分期无关(均P〉0.05)。微RNA.374b低表达组无生化复发生存率低于高表达组(P〈0.05),高表达组的生化复发时间高于低表达组(P〈0.05)。微RNA.374b表达与总体生存率无关。结论微RNA.374b的低表达与前列腺癌恶性程度有关,有望成为评价前列腺癌恶性程度及生化复发的指标。

关 键 词:微RNAs  前列腺肿瘤  生化复发  Kaplan-meiers评估

Analysis of microRNA- 374b for judging the malignancy degree and predicting the biochemical relapse in prostate cancer
Chen Yanfei,Chen Yanru,Wu Yongding,Yang Shengbang,Mo Rujun,Ling Xiaohui,Jiang Funeng,Zhong Weide.Analysis of microRNA- 374b for judging the malignancy degree and predicting the biochemical relapse in prostate cancer[J].Chinese Journal of Biomedical Engineering,2014(5):347-350.
Authors:Chen Yanfei  Chen Yanru  Wu Yongding  Yang Shengbang  Mo Rujun  Ling Xiaohui  Jiang Funeng  Zhong Weide
Institution:.( Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Department of Urology, The First People s Hospital of Guangzhou, Guangzhou Medical University, Guangzhou 510180, China)
Abstract:Objective To investigate the expression of microRNA (miR)-374b in prostate cancer (PCa) tissues and benign prostate hyperplasia (BPH), and to explore its association with malignancy degree and biochemical relapse in PCa. Methods Prostate tissue specimens were obtained from patients who underwent operations for PCa (n= 103) or BPH (n=25) in departments of urology, The First People' Hospital of Guangzhou, Guangzhou Medical University, The Second Affiliated Hospital of Sun Yat-sen University and Guangzhou Red Cross Hospital, between 2000 and 2010. The expression of miR-374b in the PCa or BPH tissues was determined by in situ hybridization. Its association with the patient age at diagnosis of PCa, presurgical PSA, clinical and pathological staging, Gleason scores, biochemical relapse, metastasis, overall survival and cancer death was statistically analyzed. According to the relative expression level of miR- 374b and a median of 4. 5, the samples were divided into the high expression and low expression groups. Kaplan- meier estimation and Log-rank test were used to evaluate the overall survival rate and the biochemical relapsefree survival rate. Results miR-374b showed low expression in PCa than that in BPH tissues (3.97±1.17 vs 4.70±0.71, P〈0,05). The expression of miR-374b was associated with Gleason score, pathological stage, metastasis, survival rate and biochemical relapse (all P〈0.05), but not with age at diagnosis of PCa, PSA and clinical stage (all P〉0.05). Low miR- 374b expression group was associated with lower rate of biochemical relapse-free survival (P〈0.05). High expression of miR-374b was associated with shorter time to biochemical relapse (P〈0.05). Expression of miR-374b was not associated with overall survival rate. Conclusion Low expression of miR- 374b is associated with the malignancy degree of PCa, and therefore can be used as a biomarker in evaluating the PCa malignancy and biochemical relapse.
Keywords:MicroRNAs  Prostatic neoplasms  Biochemical relapse  Kaplan-meiers estimate
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号